News & Updates
Filter by Specialty:

RUBY update: Dostarlimab strengthens spot in the endometrial cancer treatment arena
The addition of dostarlimab to a carboplatin-paclitaxel (CP) chemotherapy regimen confers an overall survival (OS) benefit in women with primary advanced or recurrent endometrial cancer (EC), according to the second interim analysis of the ENGOT-EN6/GOG-3031/RUBY trial part 1.
RUBY update: Dostarlimab strengthens spot in the endometrial cancer treatment arena
30 Jul 2024
Is it safe to use conditionally ordered LMWH in cancer patients with VTE?
Conditional orders of low molecular weight heparin (LMWH) based on platelet values appears safe and effective in the treatment of venous thromboembolism (VTE) in patients with malignant haematology (MH) experiencing thrombocytopenia, a study has shown. In addition, worsening or new VTE has not been reported among study participants.
Is it safe to use conditionally ordered LMWH in cancer patients with VTE?
23 Jul 2024
Can rosuvastatin protect against chemo-induced cardiotoxicity in HER2+ breast cancer?
Use of rosuvastatin is associated with a significantly lower decline in left ventricular ejection fraction (LVEF) and lower serum levels of cardiotoxicity-associated biomarkers in newly diagnosed HER2-positive breast cancer patients treated with anthracycline-based chemotherapy followed by trastuzumab, according to the results of a prospective, randomized, controlled, parallel study.